The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
about
Use of aromatase inhibitors in large cell calcifying sertoli cell tumors: effects on gynecomastia, growth velocity, and bone ageTissue physiology and pathology of aromatase.Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.Breast cancer medications and vision: effects of treatments for early-stage disease.Cell polarity, epithelial-mesenchymal transition, and cell-fate decision gene expression in ductal carcinoma in situ.Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.Nipple Aspirate Fluid Hormone Concentrations and Breast Cancer RiskTreatment options in HR⁺/HER2⁻ advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line.Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Clinical implications of estrone sulfate measurement in laboratory medicine.Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors.Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer.Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES).
P2860
Q34628355-02C3A28F-F6DC-464B-B54B-8724E33FEDB9Q34633879-C307606E-B7DD-4688-872C-47FA0A18679CQ35440357-5702A6CE-4A1D-4422-ADEC-5F990EBD9770Q35496778-6812823F-2C5B-48B8-B94D-353091E484AFQ35909091-220A0BD4-929C-46E8-8142-52EE74285373Q36484937-8B50E6BD-08EB-433D-B6AC-3E798479AFEFQ36728342-F52260C9-B2F2-4BA9-A630-6EA2437B9D91Q38250444-73E46FE5-390C-4DFA-9796-67D5445B90E1Q38717355-181E0099-257F-4C2C-8ED9-11A767A1EC70Q38737784-8AE43FA5-D87B-4DC1-9F75-451C84FEDA59Q39037694-18924BD1-DFFA-4081-A89E-3DCCAED198D0Q40703442-F8BD8A23-9AB1-45F1-AC72-1552612E1CFAQ44196222-5F6EEA6F-48F6-4B02-8C4B-5508EC38F733Q45029964-776B9CC7-C9A1-42F9-B9ED-27464033A84FQ48179087-198CFA7A-EB54-4662-AA63-DBC5FBC23063Q51393764-38D543FA-F096-4F9E-993B-EE808295F84E
P2860
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The potency and clinical effic ...... ss the breast cancer continuum
@ast
The potency and clinical effic ...... ss the breast cancer continuum
@en
The potency and clinical effic ...... ss the breast cancer continuum
@nl
type
label
The potency and clinical effic ...... ss the breast cancer continuum
@ast
The potency and clinical effic ...... ss the breast cancer continuum
@en
The potency and clinical effic ...... ss the breast cancer continuum
@nl
prefLabel
The potency and clinical effic ...... ss the breast cancer continuum
@ast
The potency and clinical effic ...... ss the breast cancer continuum
@en
The potency and clinical effic ...... ss the breast cancer continuum
@nl
P2860
P921
P356
P1433
P1476
The potency and clinical effic ...... ss the breast cancer continuum
@en
P2860
P304
P356
10.1093/ANNONC/MDQ337
P5008
P577
2010-07-08T00:00:00Z
2011-03-01T00:00:00Z